Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics

From: Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

Characteristics N (%)
Median age at diagnosis: years (min–max) 60.7 (47–78)
Lymph node status Positive 32 (76%)
Negative 10 (24%)
Her2 status Positive 3 (7%)
Negative 25 (60%)
Unknown 14 (33%)
HR status Positive 42 (100%)
Neoadjuvant chemotherapy Yes 4 (9.5%)
No 38 (90.5%)
Adjuvant chemotherapy Yes 33(78.6%)
No 9(21.4%)
Adjuvant AI treatment Yes 42(100%)
Tamoxifen before AI during adjuvant treatment Yes 9 (21.4%)
No 33 (78.6%)
Median duration of AI adjuvant treatment: months (min–max) 60.0 (41-85)
Median delay between end of adjuvant treatment and relapse: months (min–max) 25 (2–71)
Type of relapse Local 1 (2.4%)
Metastatic 41 (97.6%)
Median duration of follow-up during metastatic setting: months (min–max) 32.9 (1–75)